A randomized, double-blind, Phase 3 study to evaluate the efficacy and safety of rilzabrutinib (SAR444671) compared to placebo in adult participants with active IgG4-related disease (EFC17359 (RILIEF))

Principal Investigator

Dr Emma Culver

Contact us

Email: ouh-tr.ctfresearch@nhs.net

IRAS number

1012463